A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2020
15 07 2020
Historique:
received:
22
12
2019
revised:
16
02
2020
accepted:
16
03
2020
pubmed:
21
3
2020
medline:
12
3
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
Nintedanib enhances the activity of chemotherapy in metastatic non-small cell lung cancer (NSCLC). In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. Eligible patients had stage IB (≥4 cm)-IIIA resectable NSCLC. A safety run-in phase was followed by an expansion phase with nintedanib 200 mg orally twice a day (28 days), followed by three cycles of cisplatin (75 mg/m Twenty-one patients (stages I/II/III, Although tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls. Additional studies of the combination in this setting are not recommended. Posttreatment levels of tumor-infiltrating T cells were associated with patient survival. Use of MPR facilitates the rapid evaluation of neoadjuvant therapies.
Identifiants
pubmed: 32193228
pii: 1078-0432.CCR-19-4180
doi: 10.1158/1078-0432.CCR-19-4180
pmc: PMC7446232
mid: NIHMS1578832
doi:
Substances chimiques
Indoles
0
Docetaxel
15H5577CQD
nintedanib
G6HRD2P839
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
3525-3536Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentOn
Informations de copyright
©2020 American Association for Cancer Research.
Références
J Immunother Cancer. 2018 Jun 6;6(1):48
pubmed: 29871672
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
Chest. 2001 Nov;120(5):1584-91
pubmed: 11713138
J Clin Oncol. 2010 Jul 1;28(19):3138-45
pubmed: 20516435
J Pharmacol Exp Ther. 2018 Mar;364(3):494-503
pubmed: 29263244
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
Ann Thorac Surg. 2018 Feb;105(2):418-424
pubmed: 29217088
Lancet Oncol. 2014 Feb;15(2):143-55
pubmed: 24411639
Mod Pathol. 2003 Nov;16(11):1102-8
pubmed: 14614049
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
J Clin Oncol. 2010 Apr 10;28(11):1843-9
pubmed: 20231678
J Cancer Res Clin Oncol. 1997;123(9):469-77
pubmed: 9341895
J Thorac Oncol. 2010 Jan;5(1):49-55
pubmed: 20035185
J Immunother Cancer. 2016 Feb 16;4:9
pubmed: 26885371
J Thorac Dis. 2014 May;6 Suppl 2:S224-7
pubmed: 24868440
J Thorac Oncol. 2012 May;7(5):825-32
pubmed: 22481232
Angiogenesis. 2017 Aug;20(3):359-372
pubmed: 28283856
J Thorac Oncol. 2013 Feb;8(2):222-8
pubmed: 23287849
Lancet. 2014 May 3;383(9928):1561-71
pubmed: 24576776
Cancer Res. 2008 Jun 15;68(12):4774-82
pubmed: 18559524
Cancer Sci. 2003 Nov;94(11):1003-9
pubmed: 14611679
Lancet Oncol. 2017 Dec;18(12):1610-1623
pubmed: 29129443
J Thorac Oncol. 2013 Aug;8(8):1084-90
pubmed: 23857398
J Clin Oncol. 2008 Jul 20;26(21):3552-9
pubmed: 18506026